复方药丸在心脑血管病一级预防中的应用：克服实施障碍。
The polypill in the primary prevention of heart attacks and strokes: Overcoming barriers to implementation.
机构信息
Institute of Health Informatics, University College London, London, UK.
Population Health Research Institute, St Georges University of London, London, UK.
出版信息
J Med Screen. 2024 Jun;31(2):66-69. doi: 10.1177/09691413241235486. Epub 2024 Mar 15.
Abstract
This commentary, linked to our paper in the same issue of the , discusses the reluctance to consider and adopt the polypill in the primary prevention of heart attacks and strokes, access to the polypill as a public health service, the formulation of the polypill in current use, its prescription as an unlicensed medicine, and what can be done to facilitate the adoption of the polypill approach as a routine public health service.
摘要
本评论与本刊同期发表的论文相关，讨论了在心脏病和中风的一级预防中不愿考虑和采用复方药的问题，包括将复方药作为公共卫生服务的可及性、目前使用的复方药配方、作为非处方药物开出处方，以及为促进将复方药方法作为常规公共卫生服务采用而可以采取的措施。
相似文献
1
The polypill in the primary prevention of heart attacks and strokes: Overcoming barriers to implementation.复方药丸在心脑血管病一级预防中的应用：克服实施障碍。
J Med Screen. 2024 Jun;31(2):66-69. doi: 10.1177/09691413241235486. Epub 2024 Mar 15.
2
Comparing screening based on the NHS Health Check and Polypill Prevention Programmes in the primary prevention of heart attacks and strokes.基于国民保健制度健康检查和多药预防计划进行的一级预防心脏病和中风的筛查比较。
J Med Screen. 2024 Jun;31(2):59-65. doi: 10.1177/09691413241235488. Epub 2024 Mar 15.
3
The polypill in the primary prevention of cardiovascular disease.复方药在心血管疾病一级预防中的应用。
Fundam Clin Pharmacol. 2010 Feb;24(1):29-35. doi: 10.1111/j.1472-8206.2009.00795.x. Epub 2009 Nov 23.
4
The polypill and the prevention of heart attacks and strokes by Caroline Telfer.卡罗琳·特尔弗所著的《复方药物与心脏病发作和中风的预防》
Future Cardiol. 2013 Jul;9(4):465-6. doi: 10.2217/fca.13.29.
5
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.复方制剂用于心肌梗死和中风一级预防的成本效益分析。
Eur J Epidemiol. 2016 Apr;31(4):415-26. doi: 10.1007/s10654-016-0122-1. Epub 2016 Mar 5.
6
Polypill: the evidence and the promise.复方药：证据与前景。
Curr Opin Lipidol. 2009 Dec;20(6):453-9. doi: 10.1097/MOL.0b013e32833305a3.
7
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.多效药丸能包治百病吗？对用于心血管疾病和中风一级预防的多效药丸文献的批判性回顾。
Ann Pharmacother. 2012 May;46(5):688-95. doi: 10.1345/aph.1Q621. Epub 2012 May 8.
8
Future of polypill use for the prevention of cardiovascular disease and strokes.未来用于预防心脑血管疾病和中风的复方药。
Am J Cardiol. 2014 Aug 15;114(4):641-5. doi: 10.1016/j.amjcard.2014.05.049. Epub 2014 Jun 6.
9
What is the future of stroke prevention?: debate: polypill versus personalized risk factor modification.未来的卒中预防策略如何？辩论：多效药丸与个体化危险因素修正。
Stroke. 2010 Oct;41(10 Suppl):S35-8. doi: 10.1161/STROKEAHA.110.592022.
10
Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation.多效药丸计划预防中风并降低低收入国家的成本：从临床疗效走向实用实施。
Stroke. 2023 Feb;54(2):407-414. doi: 10.1161/STROKEAHA.122.039567. Epub 2023 Jan 23.
本文引用的文献
1
Comparing screening based on the NHS Health Check and Polypill Prevention Programmes in the primary prevention of heart attacks and strokes.基于国民保健制度健康检查和多药预防计划进行的一级预防心脏病和中风的筛查比较。
J Med Screen. 2024 Jun;31(2):59-65. doi: 10.1177/09691413241235488. Epub 2024 Mar 15.
2
The polypill and medicines access: two decades and counting.多效药丸与药物可及性：二十年仍在继续
BMJ. 2023 Aug 10;382:1847. doi: 10.1136/bmj.p1847.
3
The Polypill at 20 - What Have We Learned?20年的多效药丸：我们学到了什么？
N Engl J Med. 2022 Sep 15;387(11):1034-1036. doi: 10.1056/NEJMe2210020. Epub 2022 Aug 26.
4
Whatever happened to the polypill?
BMJ. 2017 Mar 27;356:j1474. doi: 10.1136/bmj.j1474.
5
Starting the polypill: the use of a single age cut-off in males and females.开始服用复方制剂：在男性和女性中使用单一年龄界限。
J Med Screen. 2017 Mar;24(1):50-53. doi: 10.1177/0969141316631578. Epub 2016 Jul 8.
6
Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.中国高血压人群脑卒中一级预防中叶酸治疗的疗效：CSPPT 随机临床试验。
JAMA. 2015 Apr 7;313(13):1325-35. doi: 10.1001/jama.2015.2274.
7
Quantifying the health benefits of chronic disease prevention: a fresh approach using cardiovascular disease as an example.量化慢性病预防的健康效益：以心血管疾病为例的新方法。
Eur J Epidemiol. 2014 Sep;29(9):605-12. doi: 10.1007/s10654-014-9932-1. Epub 2014 Jul 26.
8
Randomized Polypill crossover trial in people aged 50 and over.50 岁及以上人群的随机化 polypill 交叉试验。
PLoS One. 2012;7(7):e41297. doi: 10.1371/journal.pone.0041297. Epub 2012 Jul 18.
9
Aspirin in the prevention of cancer.
Lancet. 2011 May 14;377(9778):1649; author reply 1651-2. doi: 10.1016/S0140-6736(11)60665-X.
10
Reconciling the evidence on serum homocysteine and ischaemic heart disease: a meta-analysis.血清同型半胱氨酸与缺血性心脏病证据的调和：一项荟萃分析。
PLoS One. 2011 Feb 2;6(2):e16473. doi: 10.1371/journal.pone.0016473.
Zotero 插件